Table 2.
Summary of impact of pathogen inactivation (PI) treatment on platelet features compared to untreated control.
| Platelet storage feature | PI system | ||
|---|---|---|---|
| INTERCEPT | MIRASOL | THERAFLEX | |
| Metabolic activity | ± (96); ↑ (97) | ↑ (98) | ↑ (99) |
| Platelet activation (CD62P expression) | ↑ (96, 100) | ↑ (98) | ↑ (99) |
| Platelet adhesion (under flow) | ± (101); ↑ (102)a | ↓ (102); ±(103) | n.d. |
| Clot formation (thrombo-elastography) | ↓ (104) | ↑b, ↓c (105) | ↓ (99) |
| Responsiveness (to agonists) | ↓ (102); ±↓d (106)c | ↓ (98) | ± (99) |
| Platelet apoptosis (PS exposure) | ± (107); ↑ (108)a | ↑ (109) | ↑ (99) |
| Platelet microparticle release | ↑ (110) | ↑ (111) | ↑ (112) |
| Free mitochondria release | n.d. | ↑ (95) | n.d. |
↓ = decrease; ± = similar; ↑ = increase; n.d. = not determined. The references are only examples of published studies, but are not comprehensive. Differences in some study outcomes could be due to variations in production methods used (platelet-rich plasma vs BC/PCs or apheresis PCs), composition in storage solution—plasma vs platelet additive solution (in different concentration)—and assay procedures.
aAt end of storage.
bThrombus stability.
cAggregation.
dAgonist-dependent.